Payment overview · 2025
General Payments
$175.04
9 reported records · 5 companies
Healthcare provider profile · identity verified
Nathan Allan Gordon, MD
Allopathic & Osteopathic Physicians|Family Medicine · COVINGTON, KY · NPI 1508426974
Verified facts
What the public records show
CMS Open Payments records show Nathan Allan Gordon, MD received $175.04 in general payments during 2025 across 9 reported records.
ABBVIE INC. accounted for 32.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synthroid by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $56.78 | 32.4% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $45.97 | 26.3% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $36.55 | 20.9% | 2 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $18.75 | 10.7% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $16.99 | 9.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $175.04 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $56.78 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $56.78 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $45.97 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $36.55 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $19.47 | 1 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $18.75 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $17.08 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $16.99 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 82 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
82 | 27 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 399 | 120 |
| Lisinopril | Lisinopril | 299 | 92 |
| Amlodipine Besylate | Amlodipine Besylate | 240 | 71 |
| Simvastatin | Simvastatin | 232 | 63 |
| Metformin Hcl | Metformin Hcl | 211 | 61 |
| Levothyroxine Sodium | Levothyroxine Sodium | 209 | 66 |
| Hydrochlorothiazide | Hydrochlorothiazide | 202 | 60 |
| Potassium Chloride | Potassium Chloride | 168 | 45 |
| Metoprolol Tartrate | Metoprolol Tartrate | 142 | 40 |
| Omeprazole | Omeprazole | 141 | 45 |
| Pantoprazole Sodium | Pantoprazole Sodium | 135 | 42 |
| Losartan Potassium | Losartan Potassium | 130 | 38 |
| Prednisone | Prednisone | 124 | 95 |
| Diclofenac Sodium | Diclofenac Sodium | 117 | 36 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 116 | 39 |
| Metoprolol Succinate | Metoprolol Succinate | 113 | 37 |
| Furosemide | Furosemide | 108 | 40 |
| Trazodone Hcl | Trazodone Hcl | 93 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 92 | 34 |
| Glimepiride | Glimepiride | 92 | 29 |
| Allopurinol | Allopurinol | 90 | 29 |
| Carvedilol | Carvedilol | 88 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 83 | 29 |
| Eliquis | Apixaban | 82 | 27 |
| Cefdinir | Cefdinir | 75 | 69 |
| Meloxicam | Meloxicam | 71 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 65 | 23 |
| Gabapentin | Gabapentin | 65 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 62 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 60 | 25 |
| Sertraline Hcl | Sertraline Hcl | 59 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 54 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 48 | 37 |
| Azithromycin | Azithromycin | 42 | 34 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 42 | 11 |
| Atenolol | Atenolol | 38 | 11 |
| Buspirone Hcl | Buspirone Hcl | 38 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 38 | 13 |
| Mirtazapine | Mirtazapine | 38 | 15 |
| Ozempic | Semaglutide | 38 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 37 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 37 | 11 |
| Montelukast Sodium | Montelukast Sodium | 37 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 35 | 12 |
| Amoxicillin | Amoxicillin | 35 | 25 |
| Metformin Hcl Er | Metformin Hcl | 35 | 12 |
| Spironolactone | Spironolactone | 34 | 14 |
| Ondansetron Odt | Ondansetron | 32 | 28 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 32 | suppressed |
| Ezetimibe | Ezetimibe | 31 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 31 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 30 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 29 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Jardiance | Empagliflozin | 27 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 27 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | 11 |
| Clonidine Hcl | Clonidine Hcl | 25 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 25 | suppressed |
| Finasteride | Finasteride | 25 | suppressed |
| Naproxen | Naproxen | 25 | suppressed |
| Nitroglycerin | Nitroglycerin | 25 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 14 |
| Droplet Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Sucralfate | Sucralfate | 24 | suppressed |
| Cilostazol | Cilostazol | 23 | suppressed |
| Clonazepam | Clonazepam | 23 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 23 | suppressed |
| Bupropion Xl | Bupropion Hcl | 21 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 21 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 21 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 19 |
| Diazepam | Diazepam | 20 | suppressed |
| Hydrocortisone | Hydrocortisone | 20 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 19 | 11 |
| Glipizide | Glipizide | 18 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 18 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | 13 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Famotidine | Famotidine | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Cephalexin | Cephalexin | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 13 | suppressed |
| Levofloxacin | Levofloxacin | 12 | suppressed |
| Lorazepam | Lorazepam | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | 12 |
| Mupirocin | Mupirocin | 12 | 11 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Alprazolam | Alprazolam | 11 | suppressed |
| Mounjaro | Tirzepatide | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Pregabalin | Pregabalin | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $175.04 · 9 records | ABBVIE INC. | Auvelity, ELIQUIS, Heplisav-B, Kerendia, NURTEC ODT, QULIPTA, UBRELVY, ZAVZPRET | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error